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Abstract 
Purpose: To investigate the reducing effect of Morinda citrifolia capsules (MCC) on total cholesterol 
(TC) and low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemia patients.  
Methods: This study was a randomized double-blind placebo-controlled clinical trial, with 60 subjects 
placed in two groups, viz, experimental (MCC group) and placebo (P group). The first group received 
two capsules of MCC (each capsule contains 500 mg extract) while the second group received two 
capsules of placebo (comprised of 500 mg fillers) 3 times daily, for 14 days for both groups. Overnight 
fasting cubiti venous blood (3 mL) was taken from each subject each time measurements were carried 
out. TC and LDL-C were measured by spectrophotometric assay using an automated analyzer.   
Results: The results show that there was significant decrease in TC and LDL-C on day 14, compared to 
control (P group). Reduction in TC and LDL-C was 13.8 and 15.5 %, respectively. Decrease in TC and 
LDL-C levels was influenced by factors, such as age, BMI, exercise, diet, and smoking habits. In MCC 
group, the capsules significantly decreased TC levels (p < 0.05). 
Conclusion: The results suggest that 1 g MCC, given orally thrice daily, significantly reduces TC and 
LDL-C levels in patients with hypercholesterolemia.  
 
Keywords: Hypercholesterolemia, Cholesterol levels, Morinda citrifolia 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Spinal cord injury (SCI) affects several neuronal 
structures following mechanical injury [1]. 
Therefore, SCI has a complex pathophysiology. 
Because secondary injury after primary 
mechanical injury inhibits functional recovery in 
patients with SCI, research has been conducted 
for several years in an attempt to resolve this 
issue. Secondary injuries are triggered by 
inflammatory responses, which play a key role in 
the pathogenesis of SCI [2]. 
 
Any damage to the nervous system causes 
neuropathic pain (NP), which may compound 
other health problems, including diseases such 
as diabetes, surgical procedures, and traumatic 
injuries [3]. Studies have been conducted 
regarding NP treatment, which include the use of 
tricyclic antidepressants and calcium channel α2- 
δ ligands; however, satisfactory results have not 
yet been achieved [3]. In recent years, it has 
been suggested that glial activation is sufficient 
for chronic pain sensitization [4], such that the 
spinal glia should be considered when treating 
NP. Glial activation results in an increase in 
neuromodulators, pro-inflammatory cytokines, 
and chemokines, along with growth factors that 
cause pain and hypersensitivity; neuronal 
excitability is also enhanced in the spinal dorsal 
horn (SDH) [5]. 
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Various studies have shown that astrocyte 
activation depends on the phosphorylation state 
of Janus kinase (JAK) signal transducers and 
activators of the transcription 3 (STAT3) 
signaling pathway [6,7]. During activation of 
spinal astrocytes, inhibition of the JAK-STAT3 
pathway can reduce the pain response, as well 
as peripheral nerve injury hyperexcitability in 
SDH neurons [8]. Inhibition of the cytokine 
signaling 3 (SOCS-3) protein results in feedback 
regulation such that the JAK-STAT3 pathway 
and NP are suppressed [8]. 
 
Tamoxifen has been shown to be a potent 
inhibitor of cell swelling in anion channels in 
experimental models of ischemic stroke [9, 10]. It 
has been reported that, along with the anion 
channels that are affected by the swelling of 
astrocytes, various pathways involved in central 
nervous system (CNS) damage are inhibited by 
tamoxifen [11]. Decreases in peroxynitrite levels 
in ischemia, along with removal of reactive 
oxygen species, have been attributed to 
tamoxifen [12]. It has been reported that anti-
inflammatory responses in mouse and rat 
microglial cells are triggered by 
lipopolysaccharide-induced signaling cascades 
and activation of proteins [13]. 
 
In this study, we explored the inhibitory effects of 
intrathecal tamoxifen on neuroinflammation and 
the spinal astrocytic pathway following traumatic 




Sprague-Dawley rats (220 – 250 g) were kept in 
a temperature-controlled environment (22 – 25 
ºC) under a 12 h/12 h light/dark cycle, with free 
access to water and food. Every effort was made 
to minimize the suffering and pain of the animals; 
the experiments were performed according to the 
ethical guidelines of Changzhou Central Hospital. 
Written approval (no. CHC 130215) was obtained 
from the Ethical Committee of Changzhou 
Central Hospital for treatment of the experimental 
animals and the animal studies followed the 
guidelines of European Commission [14]. 
 
Tamoxifen (Sigma-Aldrich, St. Louis, MO, USA) 
was dissolved in 2 % dimethyl sulfoxide (DMSO; 
1 mg/mL) and administered intrathecally 
according to the guidelines established in 
previous reports [9,10]. The rats were divided 
into three groups: sham control (n = 21; only 
normal animals were included in this group); SCI 
(n = 21; only SCI was performed and normal 
saline was injected into the animals to make up 
for the shortfall in blood volume due to no drug 
being administered); and tamoxifen [n = 42; 
tamoxifen was administered at different 
concentrations to two subgroups (both n = 21; 
tamoxifen concentrations of 1 and 5 mg/kg/day) 
at different intervals]. 
 
It has been reported in previous studies that 
motor dysfunction has a pronounced effect on 
nociceptive behavioral test outcomes [15]. 
Therefore, rotarod testing was performed to 
evaluate the possible influence of intrathecal 
tamoxifen on motor function in the injured rats. 
For this purpose, rats were tested using an 
accelerating rotating rod (model 7650; Ugo 
Basile, Varese, Italy). Rats were placed on the 
rotarod after 1 min of training; the rod was 
linearly accelerated from 4 to 40 rpm over 5 min. 
The rats completed 3 runs at 10-min intervals, 
and the elapsed time before falling on each run 
was recorded for each rat individually at the 
outset, and then again for the different groups. 
After intrathecal administration of tamoxifen and 
saline at 30 min, the tests were performed daily 
for 7 d. The time taken by each rat to fall from the 
rotarod was noted and the final results were 
expressed as a percentage of each rat’s baseline 
time. 
 
The rats were anesthetized with pentobarbital 
(60 mg/kg) and transcardially perfused using 200 
mL of 5 mM sodium phosphate buffered saline 
[PBS; 0.9 % (w/v); pH 7.3] and 500 mL 4 % 
paraformaldehyde in 0.1 M phosphate buffer at 
pH 7.4. The L5 spinal cord segments of the rats 
were harvested, immersed in 30 % sucrose 
overnight, and kept at 4 ºC. Transverse spinal 
sections were cut on a cryostat (Leica CM1800; 
Heidelberg, Germany) and rinsed three times in 
PBS at pH 7.4, with 10-min intervals between 
each rinsing. Then, sections were washed with 
0.01 M PBS containing 10 % normal goat serum 
and 0.3 % Triton X-100 at 37 ºC for 1 h for 
blocking. After 2 h incubation at room 
temperature, further incubation at 4 ºC for 48 h 
was done with a mixture of anti-pSTAT rabbit 
immunoglobulin G (IgG) (1:1,000; Cell Signaling 
Technology, Danvers, MA, USA) in a mixture of 
PBS and 0.3% Triton X-100, 5 % (v/v) donkey 
serum (PBS-XCD), and 0.25 % λ-carrageenan. 
Then, washing was performed using 0.01 M PBS 
for 10 min, and sections were incubated at room 
temperature with a mixture of 10 µg/mL Alexa 
488-conjugated donkey anti-rabbit IgG. All 
sections were fixed on glass slides after staining 
and covered using 50 % glycerol and 2.5 % 
triethylenediamine (as an anti-fading agent) in 
0.05 M PBS. Sections were observed under a 
laser scanning microscope (FV 1000; Olympus, 
Tokyo, Japan) with appropriate settings for 
proper visualization and acquisition of clear 
digital images. 
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L5 spinal segments were dissected on ice and 
the left dorsal part of the spinal cord was 
homogenized. Segments were further split in a 
handheld pestle with sodium dodecyl sulfate 
(SDS) sample buffer (10 mL/mg/tissue) and a 
mixture of phosphatase and proteinase inhibitors 
(Sigma-Aldrich). The bicinchoninic acid (BCA) 
method was used for quantification of protein 
concentrations. Samples were boiled for 8 min in 
water and loaded onto an SDS polyacrylamide 
gel (Bio-Rad Laboratories, Hercules, CA, USA) 
before being transferred a to polyvinylidene 
difluoride (PVDF) membrane (Immobilon™-P; 
Millipore, Billerica, MA, USA). A 5 % bovine 
serum albumin (BSA) solution was applied for 2 
h to block membranes, and the following primary 
antibodies were applied at 4 ºC overnight: anti-
pSTAT3 rabbit IgG (1 : 300; Cell Signaling 
Technology), rabbit anti-pJAK IgG (1 : 300; Cell 
Signaling Technology), and anti-β-actin mouse 
IgG (1 : 300; Sigma-Aldrich). Membranes were 
then incubated for 2 h with secondary antibodies, 
horseradish peroxidase (HRP)-conjugated 
donkey anti-rabbit IgG (1 : 5,000; Zhongshan, 
Beijing, China) and HRP-conjugated donkey anti-
mouse IgG (1: 5,000; Zhongshan). The 
membranes were rinsed thrice (10 min per rinse) 
using Tris-buffered saline and Tween 20 (TBST). 
Protein blots were analyzed using Labwork 
software (Ultra-Violet Products, Cambridge, UK), 
and target protein levels were normalized against 
β-actin levels and compared among the 
experimental and control groups; intensity was 
quantified using densitometry. 
 
An enzyme-linked immunosorbent assay (ELISA) 
was performed on all samples after isolating the 
left dorsal horns of the L5 spinal segments of all 
animals according to the method used for 
Western blotting. The amounts of interleukin (IL)-
1β, IL-6, and tumor necrosis factor (TNF)-α were 
measured using a Multi-Analyte ELISArray Kit 
(Mix-N-Match; SABiosciences, Frederick, MD, 
USA). The manufacturer’s protocol was followed 




The data are presented as mean ± standard 
deviation (SD). Analysis of the rotarod testing, 
Western blot and ELISA data were performed 
using SPSS software (ver. 16.0; SPSS Inc., 
Chicago, IL, USA) and by analysis of variance 
(ANOVA) with Bonferroni confidence interval 





Nociceptive behavioral test performance can be 
impaired significantly by motor dysfunction in 
rats. However, in this study, intrathecal tamoxifen 
had no obvious effect on the motor function of 
rats after 30 min of administration relative to their 
own baselines (Figure 1). 
 
An effect of intrathecal tamoxifen on the 
phosphorylation of STAT3 was observed; 
increased immunoreactivity was seen in rats with 
SCI administered tamoxifen compared with the 
sham controls, and comparatively weak 
immunoreactivity was observed in all subgroups 
when tamoxifen was administered after SCI 
(Figure 2). 
 
Figure 1:  Effect of intrathecal tamoxifen on motor performance in the rotarod test Tamoxifen at 1 and 5 mg/kg 
did not have a pronounced effect on motor performance in rats with traumatic spinal cord injury (SCI) compared 
with the control group 
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Figure 2: Effect of intrathecal tamoxifen on STAT3 phosphorylation in rats with SCI. (a) Increased pSTAT3 
immunoreactivity was visible in rats with SCI; in these animals, there was an accumulation of pSTAT3 in spinal 
astrocytes. (b) Weak immunoreactivity of pSTAT3 was evident in normal controls. (c) Attenuation of pSTAT3 was 
evident in photomicrographs of rats treated with 5 mg/kg/day tamoxifen. (d) A comparatively less efficient 
pSTAT3 immunoreactivity result was evident in photomicrographs of rats treated with 1 mg/kg/day tamoxifen 
 
      Figure 3: Western blot analysis showing the pSTAT3 levels of the different rat groups 
 
To observe inhibition of the JAK2-STAT3 
pathway after tamoxifen administration, JAK2 
and STAT3 phosphorylation were examined 
using Western blot analysis. Significantly 
elevated levels of pSTAT3 were seen in rats with 
SCI compared with rats that were treated with 
tamoxifen (p < 0.05) (Figure 3). 
pJAK2 expression was significantly inhibited in 
tamoxifen-treated rats versus the sham control 
group (p < 0.05) (Figure 4). 
Elevated TNF-α, IL-1β, and IL-6 levels were 
present in rats with SCI than sham control group. 
However, treatment with tamoxifen significantly 
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(p < 0.05) reduces the expression of 








Figure 5: Effect of tamoxifen on pro-inflammatory cytokine levels. (a) Graphs showing decreased interleukin (IL)-




In this study, we observed that intrathecal 
administration of tamoxifen, at doses of 1 and 5 
mg/kg/day, inhibits the proliferation of reactive 
astrocytes in the lumbar SDH; however, the 5 
mg/kg/day dose was more effective. Astrocytic 
activation is regulated by activation of the 
JAK/STAT3 pathway; this activation was 
inhibited by administration of tamoxifen in injured 
rats, resulting in significantly reduced pJAK2 and 
pSTAT3 levels. A lower level of pro-inflammatory 
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cytokines was also observed, illustrating the anti-
inflammatory effects of tamoxifen. Taken 
together, these results in rats with L4 and L5 
injuries suggest that tamoxifen has good 
therapeutic potential. 
 
Neuroprotective effects of tamoxifen have been 
reported in different studies and injury models. In 
an intracerebral hemorrhage model, a reduction 
in peri-hematomal brain edema was reported 
following use of tamoxifen [16], while reductions 
in pro-inflammatory cytokines and cell apoptosis 
in rats with SCI were reported by an earlier study 
[17]. In this study, we explored the possible role 
of tamoxifen in the JAK/STAT3 pathway in a 
spinal injury rat model. 
 
Several studies have indicated that reactive 
astrocytes and microglia are important for 
maintaining NP [18]. Glial cells release different 
inflammatory stimulants, including neurotrophic 
factors, prostaglandins, and cytokines, which 
change the polarization of afferent neurons and 
result in the transmission of pain stimuli to the 
CNS [19]. Therefore, reducing pain and 
inflammation via a single agent has great 
therapeutic potential for treating spinal injuries in 
rats. We used 1 and 5 mg/kg/day tamoxifen 
doses based on traditional Chinese medicine 
regimens for treating different disorders. 
 
It has been reported that the JAK-STAT pathway 
is an important signal transducer that responds 
to different external stimuli and transfers signals 
for cell migration, proliferation, and apoptosis 
from the cell surface to the cell nucleus [7]. 
Under conditions of astrogliosis, the JAK/STAT3 
pathway plays a role as shown in models of NP, 
and brain ischemia [6,7].  
 
The role of pro-inflammatory cytokines in spinal 
injuries has been well-established. It has been 
reported that proinflammatory cytokines IL-1β 
and TNF-α are important in initiating NP, which is 
an important and painful pathological condition in 
traumatic spinal cord injuries, while IL-6 is 




The findings of this study show that 
proinflammatory cytokine levels are attenuated 
by tamoxifen at 5 mg/kg/day. This is consistent 
with inhibition of JAK/STAT3 pathway. Thus, 
tamoxifen at 5 mg/kg/day inhibits the JAK/STAT3 
pathway, which in turn attenuates the expression 
of proinflammatory cytokines, eventually leading 
to anti-inflammatory effects as well as 
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